Evidence map›Paper›PMID 37120727›Full record

Trial reportThe Journal of urology2023

Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial.

Thomas A Masterson, Manuel Molina, Braian Ledesma, Isaac Zucker, Russell Saltzman, Emad Ibrahim, Sunwoo Han, Isildinha M Reis, Ranjith Ramasamy

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. An overview of the Canadian landscape on the use of restorative therapies for erectile dysfunction and Peyronie's disease.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Thomas A MastersonDesai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, Florida.ORCID 0000-0001-5211-9271
Manuel MolinaDesai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, Florida.
Braian LedesmaDesai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, Florida.
Isaac ZuckerDesai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, Florida.
Russell SaltzmanDesai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, Florida.
Emad IbrahimDesai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, Florida.
Sunwoo HanBiostatistics and Bioinformatics Shared Resources, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Isildinha M ReisBiostatistics and Bioinformatics Shared Resources, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Ranjith RamasamyDesai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, Florida.
University of Miami · US

Funding

Disease Modifying Treatment Using Combined Shockwave Therapy and Platelet Rich Plasma In Microvascular Erectile DysfunctionR01DK130991 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI IBRAHIM, EMAD · 2021 to 2023
$921k
NIDDK NIH HHS R01 DK130991
6 · The paper itself

Abstract

purposeWe assessed the safety and efficacy of 2 injections of platelet-rich plasma for treating mild to moderate erectile dysfunction by conducting a prospective, randomized, double-blind, placebo-controlled clinical trial. MATERIALS AND

methodsMen with mild to moderate erectile dysfunction (International Index of Erectile Function scores 11-25) were randomized to receive either 2 injections of platelet-rich plasma or placebo separated by 1 month. Primary outcome was percentage of men meeting minimum clinically important difference at 1 month after the second injection. Secondary outcomes were change in International Index of Erectile Function at 1, 3, and 6 months, and changes in penile vascular parameters and adverse events at 6 months.

resultsWe randomized 61 men: 28 into platelet-rich plasma and 33 into placebo. There was no difference between groups in percentage of men meeting minimum clinically important difference at 1 month: 14 (58.3%) in platelet-rich plasma vs 15 (53.6%) in placebo (

conclusionsThe results of our prospective, double-blind, randomized, placebo-controlled clinical trial suggest that 2 injections of intracavernosal platelet-rich plasma separated by 1 month in men with mild to moderate erectile dysfunction is safe, but we found no difference in efficacy between platelet-rich plasma and placebo.

Indexed as

Erectile DysfunctionDouble-Blind MethodHumansMalePenisProspective StudiesTreatment Outcomeclinical trialerectile dysfunctionplatelet-rich plasma

Identifiers

PMID37120727
PMCPMC10330773
OpenAlexW4367549671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.